MX2016005285A - Conjugados de somatostatina y sus analagos. - Google Patents

Conjugados de somatostatina y sus analagos.

Info

Publication number
MX2016005285A
MX2016005285A MX2016005285A MX2016005285A MX2016005285A MX 2016005285 A MX2016005285 A MX 2016005285A MX 2016005285 A MX2016005285 A MX 2016005285A MX 2016005285 A MX2016005285 A MX 2016005285A MX 2016005285 A MX2016005285 A MX 2016005285A
Authority
MX
Mexico
Prior art keywords
somatostatin
conjugates
analogs
hydrogels
carriers
Prior art date
Application number
MX2016005285A
Other languages
English (en)
Inventor
V Santi Daniel
Ashley Gary
l schneider Eric
Hearn Brian
Original Assignee
Prolynx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolynx Llc filed Critical Prolynx Llc
Publication of MX2016005285A publication Critical patent/MX2016005285A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen conjugados de portadores e hidrogeles para controlar la vida media biológica de somatostatina y sus análogos.
MX2016005285A 2013-10-22 2014-10-22 Conjugados de somatostatina y sus analagos. MX2016005285A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361894226P 2013-10-22 2013-10-22
PCT/US2014/061844 WO2015061503A1 (en) 2013-10-22 2014-10-22 Conjugates of somatostatin and its analogs

Publications (1)

Publication Number Publication Date
MX2016005285A true MX2016005285A (es) 2016-10-28

Family

ID=52993525

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005285A MX2016005285A (es) 2013-10-22 2014-10-22 Conjugados de somatostatina y sus analagos.

Country Status (10)

Country Link
US (2) US10086049B2 (es)
EP (1) EP3060230A4 (es)
JP (1) JP2016534064A (es)
KR (1) KR20160075665A (es)
CN (1) CN106232131A (es)
AU (1) AU2014340095A1 (es)
CA (1) CA2928407A1 (es)
MX (1) MX2016005285A (es)
SG (2) SG11201603115YA (es)
WO (1) WO2015061503A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3555280A4 (en) * 2016-12-19 2020-09-09 The Regents of The University of California PEPTIDES SENSITIVE TO TWO ENZYMES
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
EP3630189A4 (en) * 2017-05-24 2021-06-23 The Board of Regents of The University of Texas System LINKER FOR ANTIBODY MEDICINAL CONJUGATES
JP6984923B2 (ja) * 2017-09-19 2021-12-22 イミュンワーク インク.Immunwork Inc. アルブミンとの強化された結合親和性を有する医薬構築物
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
JP7784993B2 (ja) * 2019-09-30 2025-12-12 奥金生命科学（宜興）有限公司 タンパク質－巨大分子コンジュゲート及びその使用方法
WO2021119268A1 (en) * 2019-12-11 2021-06-17 The General Hospital Corporation Methods for cell imaging
CN114409736B (zh) * 2022-01-28 2023-09-15 中国科学院精密测量科学与技术创新研究院 一种基于两亲性寡肽的定相排列介质及其制备方法和应用
KR102835630B1 (ko) * 2022-02-25 2025-07-22 앱티스 주식회사 신규 항체 약물 접합체
AU2023351002A1 (en) * 2022-09-26 2025-03-13 Boston Scientific Scimed, Inc. Crosslinked radiopaque networks for medical applications

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214792B1 (en) * 1996-04-12 2001-04-10 David Lew Simon Method for treating acute and severe diarrhea
AU2000202A (en) * 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
EP1888043A4 (en) 2005-03-11 2010-07-28 Endo Pharmaceuticals Solutions OCTREOTIDE FORMULATIONS WITH CONTROLLED RELEASE
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
JP5536053B2 (ja) 2008-06-25 2014-07-02 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド． 離型剤を有するオクトレオチドインプラント
EP2306986B1 (en) * 2008-06-26 2018-03-21 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
US8640315B1 (en) 2009-10-28 2014-02-04 Robert E. Nikkel Rotating adapter assembly
EP3378468A1 (en) * 2010-01-13 2018-09-26 Ipsen Pharma S.A.S. Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
US8703907B2 (en) 2010-05-05 2014-04-22 Prolynx Llc Controlled drug release from dendrimers
JP5977229B2 (ja) 2010-05-05 2016-08-24 プロリンクス リミテッド ライアビリティ カンパニー 巨大分子共役体からの徐放
DK2566334T3 (en) 2010-05-05 2018-07-23 Prolynx Llc MANAGED PHARMACEUTICAL RELEASE FROM SOLID CARRIERS
EP2755691B1 (en) * 2011-09-07 2018-08-22 Prolynx LLC Hydrogels with biodegradable crosslinking
BR112014013693B1 (pt) 2011-12-05 2023-01-31 Camurus Ab Pré-formulação, e, uso de uma pré-formulação

Also Published As

Publication number Publication date
KR20160075665A (ko) 2016-06-29
AU2014340095A1 (en) 2016-05-26
US10086049B2 (en) 2018-10-02
SG11201603115YA (en) 2016-05-30
CN106232131A (zh) 2016-12-14
US20180296648A1 (en) 2018-10-18
CA2928407A1 (en) 2015-04-30
SG10201803370XA (en) 2018-06-28
EP3060230A4 (en) 2017-06-14
US10413594B2 (en) 2019-09-17
WO2015061503A1 (en) 2015-04-30
JP2016534064A (ja) 2016-11-04
EP3060230A1 (en) 2016-08-31
US20160271227A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
MX2016005285A (es) Conjugados de somatostatina y sus analagos.
MX2020014121A (es) Agonistas parciales del receptor de insulina.
IN2013KO01129A (es)
MY187622A (en) Color stable red-emitting phoshors
JO3755B1 (ar) تركيبات تستوستيرون
IN2013DE00266A (es)
MX381841B (es) Anticuerpos anti-jagged y métodos de uso.
AU2014224814A8 (en) Novel halogen-substituted compounds
NZ630549A (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide
MY187959A (en) Reactor
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
IN2013KO01130A (es)
GEP201706636B (en) Galactagogue compositions based on phosphatidylserine
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
IN2015KN00386A (es)
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA76716U (uk) 5,7-ДИМЕТИЛ-2-ОКСО-6-ФЕНІЛАЗО-ТІАЗОЛО[4,5-b]ПІРИДИН-3-ІЛГІДРАЗОНИ АЦЕТАТНОЇ КИСЛОТИ, ЩО ПРОЯВЛЯЮТЬ АНТИЕКСУДАТИВНУ ДІЮ
UA79072U (en) (4-tert-butylperoxy-4-methylpentyl)methacrylate
IN2013KO01440A (es)
IN2013KO01329A (es)
IN2013KO01319A (es)
UA72478U (ru) Применение полентара как средства фригопротекторного действия
UA103911U (ru) Средство с вазодилатирующей активностью
IN2012DE01204A (en) "shikhar technology"